H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals to $620 from $568 and maintained a Buy rating. H.C. Wainwright increased its assumptions for Rezdiffra penetration after consulting with 6 key opinion leaders/KOLs. They reported real-world uptake of the drug among patients with metabolic dysfunction-associated steatohepatitis/MASH who have F2/F3 liver fibrosis. Des ...